Idorsia’s Quviviq approved for adults with chronic insomnia disorder
The EC’s decision on the insomnia treatment was supported by phase 3 trial results
Read More
Tag: Quviviq
CHMP recommends Idorsia’s dual acting treatment Quviviq for insomnia patients
Quviviq can be used on a long-term basis, addressing a key limitation of existing therapies
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
